56, 95% CI=1.26-5.22, P = 0.01; OR=4.60, 95% CI=1.55-13.65, P = 0.006 for HCV genotype 1b patients). Interestingly, Patients with GC_rs222020 TC genotype are easily to have liver fibrosis (F2>7.3KPa) (OR=1.74, 95% CI=1.08-2.81, P = 0.023). We did not find any relationship between GC_rs7041, DHCR7 and treatment Erlotinib concentration response, neither did GC_ rs7041, CYP2R1, DHCR7 and liver fibrosis. Conclusions: In conclusion, CYP2R1 AA genotype

and GC_rs222020 TC genotype contribute to successful treatment outcome achievement, while GC_rs222020 TC genotype seems to lead to a higher pick-up rate of liver fibrosis. Association between CYP2R1, GC_rs222020 and treatment response in chronic HCV infected patients treated with IFN-α2b/ ribavirin M: major allele; m: minor allele; RVR: rapid viral response; CEVR: complete early Opaganib ic50 viral response; ETVR:

end of treatment viral response. Disclosures: The following people have nothing to disclose: Ruqi Mei, Yu Pan, Xiumei Chi, Xiaomei Wang, Ruihong Wu, Xiuzhu Gao, Jinglan Jin, Ge Yu, Jing Jiang, Junqi Niu Background: HCV infection is a leading contributor toward advanced liver disease, transplantation, and liver-related deaths in Argentina. A modeling approach was used to estimate the progression of the HCV epidemic and measure the burden of HCV-related morbidity and mortality. Methods: Age- and gender-defined cohorts were used to follow the viremic population in Argentina, and estimate HCV incidence, prevalence, hepatic complications, and mortality. Base case assumptions MCE were derived from the literature

and country-specific data sources. The relative impact of two scenarios on HCV-related outcomes was assessed: 1) increased sustained virologic response (SVR), and 2) increased SVR and treatment. Results: Under the base case, viremic prevalence is estimated to have peaked in 2002 (381,840 cases), declining 12% to 337,120 by 2014. Incident cases peaked at 22,340 in 1989, declining 91% to 1,900 cases in 2014. It is estimated that 70% of the infected population was born between 1950 and 1975 in 2014. By 2030, the infected population is projected to decline to 237,420 cases, a 30% decrease from 2014 (337,120 cases), largely due to mortality. Compensated cirrhosis is projected to peak at 63,000 cases after 2030, a 62% increase from 2014, while decompensated cirrhosis will peak after 2030 at 8,580 cases, an 81% increase from 2014. HCC cases also peak after 2030 at 3,760 cases, a 93% increase from 2014. Under Scenario 1, SVR increased to 85% (G3), 90% (G1/4) and 95% (G2) in 2016. Compared to the base case, there was a 0.3% reduction in prevalent cases, and a 0.2% reduction in liver-related deaths by 2030. Given low treatment rates, incident cases of liver cancer and decompensated cirrhosis decreased <1%, as compared to the base case in 2030. Under Scenario 2, the same increases in SVR were modeled, with gradual increases in the annual diagnosed and treated populations to 14,800 and 12,000 cases, respectively.